Enact Holdings EVP Evan Stolove sells $991,668 of company stock

Enact (ACT) reported Q2 2026 results ahead of expectations: adjusted operating income of $177M and $1.26 EPS vs $1.19 estimates (+5.9% beat), and revenue of $317.3M vs $314.49M (+0.9% beat). The stock was stable after-hours, while technicals show shares near a 52-week high ($50.56) and up 33% over the past year. Separately, EVP/General Counsel Evan Stolove sold 20,024 shares for $991,668 at a weighted average of $49.524, slightly reducing insider holdings to 32,003 shares.

Analysis

The real signal in NVDA is not a one-day beta squeeze; it is confirmation that AI capex is still being budgeted into the next spend cycle. That favors the highest-leverage beneficiaries of incremental data-center dollars — semicap equipment, networking, power/thermal, and advanced packaging — while lower-quality AI software names may lag as capital rotates toward proven monetizers. Near term, the move can persist for days, but the more important 1-3 month path is estimate revisions and buy-side re-risking across SMH/SOXX constituents.

ACT is a much weaker signal. A small insider sale near the highs is usually low-information unless it is repeated by multiple executives or paired with deteriorating credit metrics; the real driver for mortgage insurers is housing turnover and loss severity, not a single quarter beat. If rates stay sticky, volume growth is capped and the valuation starts to matter more; if rates fall, new insurance written can re-accelerate and offset the current overvaluation argument.

The contrarian risk is extrapolation: investors may be overpaying for NVDA durability while underestimating how quickly the market can rotate from leaders to secondaries after a blockbuster print. For ACT, consensus may be too complacent about how little margin of safety is left at the top of the range. Falsifiers: NVDA failing to hold the post-earnings gap low and/or semis breadth rolling over within 2-3 sessions; ACT showing reacceleration in new insurance written and no broadening of insider selling into the next quarter.

Key Decisions for Investors

• Add to NVDA on the first meaningful pullback over the next 1-5 sessions; use a stop on a break of the post-earnings gap low. Risk/reward is favorable for a momentum continuation trade, but expect upside to come more from multiple support than another large revision.
• Prefer a basket expression: long SMH or SOXX vs. short a weaker-quality AI/software basket over 1-3 months. The thesis is that the earnings print extends the semiconductor capex cycle more than it changes software monetization, creating relative performance dispersion.
• Avoid chasing ACT here; if you need exposure, consider a small tactical short or hedged short in ACT versus RDN or MTG over 1-3 months. The trade works if mortgage-rate relief does not arrive and valuation compresses, but it should be sized modestly because the fundamental signal is not strong.
• If buying NVDA exposure, prefer defined-risk calls or call spreads rather than outright equity for 1-2 months. This captures post-print follow-through while limiting drawdown if the move proves to be an exhaustion rally.
• Set an alert on semis breadth: if SOXX/SMH fail to confirm NVDA within 2-3 sessions, take partial profits on momentum longs and rotate toward beneficiaries of the capex spend, not the headline leader.